Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol’s Baraclude Beats Hepsera In Two-year Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

Potent rival Viread aims to shake up hepatitis B market.

You may also be interested in...

As It Prepares for a Future with Wyeth, Pfizer Reports Ho-Hum Q1 Results

Pfizer’s first-quarter results were down, but in line with the company’s and Wall Street’s expectations.

Gilead Gets Positive Recommendation From EU Committee To Market Viread For Hepatitis B

Company also awaits August PDUFA date for the same indication in the United States.

Baraclude Bests Hepsera On Viral Load Reduction In HBV Patients – Bristol Study

Study shows that 58 percent of Baraclude-treated patients achieved undetectable viral load at 48 weeks versus 19 percent taking adefovir.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts